Gaithersburg, MD - Seven months after an FDA advisory panel voted nine to one to recommend approval of the Xience V everolimus-eluting stent (Abbott Vascular), the FDA has granted marketing approval ...
NATICK, Mass., Boston Scientific Corporation releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March ...
The PROMUS and XIENCE V stent systems are investigational devices in the U.S. and not yet approved for sale. PROMUS is a private-labeled XIENCE V everolimus-eluting stent system manufactured by Abbott ...
Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent NATICK, ...
A clinical study has shown Abbott Laboratories' "Xience," a drug-coated stent, to be more effective than Boston Scientific's Taxus device. This result clears Abbott to seek FDA approval for the Xience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback